First AD

Second AD

Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM 

Video content above is prompted by the following:

In preparing patients to receive CAR T, what is your optimal strategy for bridging therapy?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Multiple Myeloma

BMS-22-OSD1240 - /clinical/multiple-myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory 

Peer Exchange

Panelists discuss their optimal strategies for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T in the treatment of relapsed/refractory multiple myeloma (R/R MM).